key: cord-0279449-mw1gypul
authors: Larsen, Sasha E.; Erasmus, Jesse H.; Reese, Valerie A.; Pecor, Tiffany; Archer, Jacob; Kandahar, Amit; Hsu, Fan-Chi; Reed, Steven G.; Baldwin, Susan L.; Coler, Rhea N.
title: RNA-based vaccine demonstrates prophylactic efficacy against Mycobacterium tuberculosis challenge in a mouse model
date: 2022-02-23
journal: bioRxiv
DOI: 10.1101/2022.02.23.481669
sha: 7d2486f957be37ee244bebda5816e68ebe2ff00b
doc_id: 279449
cord_uid: mw1gypul

Mycobacterium tuberculosis (Mtb) is an opportunistic bacterial pathogen that causes tuberculosis disease (TB) and exerts an extensive burden on global health. The complex intra- and extracellular nature of this bacterium, coupled with different disease stages have made mechanistic studies evaluating the contributions of innate and adaptive host immunity challenging. In this work we leveraged two delivery platforms as prophylactic vaccines to assess immunity and subsequent efficacy against low dose and ultra-low dose aerosol challenge with Mtb H37Rv in C57BL/6 mice. Our proof-of-concept TB vaccine candidate ID91 was produced as a fusion protein formulated with a synthetic TLR4 agonist (glucopyranosyl lipid adjuvant in a stable emulsion) or as a replicating-RNA (repRNA) formulated in a nanostructured lipid carrier (NLC). Results from this work demonstrate that protein subunit- and RNA-based vaccines preferentially elicit cellular immune responses to different ID91 epitopes. In a single prophylactic immunization screen, both platforms reduced pulmonary bacterial burden compared to controls. Excitingly, in prime-boost strategies, groups that received heterologous RNA-prime, protein-boost or combination (simultaneous in different sites) immunizations demonstrated the greatest reduction in bacterial burden and a unique humoral and cellular immune response profile. These data are the first to report that repRNA platforms are a viable system for TB vaccines and should be pursued with high priority Mtb antigens containing CD4+ and CD8+ T cell epitopes.

For the first time in a decade, 2020 saw an increase in annual deaths (1.5 million total) caused 39

by Mycobacterium tuberculosis (Mtb) to lead to a further half-million preventable TB deaths 6 . This dual assault from respiratory 45 pathogens is most heavily felt by low and middle income countries (LMICs) which endure a 46 disproportionate burden of TB disease 7 , and are also suffering from a lack of access to vaccines 47

for SARS-CoV-2 8 . Moreover, within Mtb, drug resistance (DR) is steadily increasing globally. For 48 the past five years, nearly 0.5 million patients infected with Mtb annually develop resistance to 49 front-line antibiotic rifampicin and approximately 80% of those harbor multidrug-resistance 50

(MDR) 1,2,5 . Novel antibiotic regimens 9-13 are being developed but by many models are insufficient 51 alone to combat this epidemic 14, 15 . Specifically designed low cost and effective TB vaccines for 52

prevention of infection (POI), or complementary prevention of active disease (POD) endpoints are 53 desperately needed 16 . 54

While clinical trials suggest that Mycobacterium bovis bacille Calmette-Guérin (BCG) may prevent 55

Mtb infection in adolescents 17 , and subunit adjuvanted vaccine candidate M72/AS01E 18,19 56

prevents TB disease in a subset of interferon gamma release assay (IGRA) positive individuals, 57

there is no currently approved vaccine for POI or POD in adults. This lag is partially due to the 58 fact that financial resources available for testing drug and vaccine candidate regimens in human 59 clinical settings are disproportionately low for TB, relative to the global burden of disease. 60

Addressing improved efficacy of prophylactic vaccines against Mtb and supply and costs of 61 manufacturing materials are all required to ensure that a vaccine is readily available to those who 62 need it. Thankfully, renewed enthusiasm for TB vaccine research has been stimulated largely by 63 two main pillars of preclinical and clinical advancements. First, the pursuit of correlates of 64 protection (COP) against TB which are refining the immune players in the fight against infection 65 and disease, and second, the pursuit of cutting edge vaccine delivery platforms. 66

Historically the vaccine pipeline has relied on CD4+ T helper 1 (TH1) type responses as a 67

benchmark for immunogenicity stage-gating of vaccine candidates. However, the full mechanism 68 of protection has yet to be determined 20 , and several preclinical and clinical reviews suggest the 69 CD4+ TH1 subset producing proinflammatory cytokine IFNγ alone is not sufficient nor fully 70 predictive of clinical efficacy 21-24 . Indeed, protection from Mtb infection and TB disease is likely a 71 multifaceted process involving many cell types beyond canonical CD4+ T cells, and our focus 72

here is on Mtb-antigen specific CD8+ T cells. like protein), Rv2389 (RpfD), Rv3478 (PPE60) and Rv1886 (Ag85B) ( Figure 1A) . These antigens 108

were selected as candidates for Mtb vaccines based on their lack of human sequence homology 109

and their ability to induce an ex vivo IFN-γ response in PPD+ human peripheral blood 110 mononuclear cells (PBMC), suggesting they are immunogenic in humans 52,53 . ID91 antigens were 111 cloned into an alphavirus repRNA backbone as previously described 48 ( Figure 1B ). This repRNA 112

platform has a number of advantages including 1) a subgenomic promoter to amplify expressioin 113 of the antigen of interest, 2) exclusive cytoplasmic activity with no risks of nuclear genomic 114 integration, and 3) sustained antigen production in the presence of adjuvanting innate responses 115 that allows for dose sparing and strong cellular responses 48,49 . Using western blotting we observed 116 efficient expression of the ID91 antigens from repRNA ID91 in BHK cells (Figure 1C ), 117

demonstrating this platform is amenable to Mtb antigen expression. Partnering repRNA with 118 delivery formulations provides stability and protection from RNAses and removes the requirement 119

for viral delivery, eliminating anti-vector immunity which has been detrimental for promising 120

candidates. Here we leveraged a first-generation nanostructured lipid carrier (NLC) 48 as a two-121

vial approach with ID91-repRNA. C57BL/6 mice were vaccinated two times, two weeks apart with 122 either ID91 fusion protein + TLR4 agonist, glucopyranosyl lipid adjuvant formulated in a stable 123 emulsion (GLA-SE) or ID91-repRNA + NLC to evaluate preliminary immunogenicity. Splenocytes 124 from both immunized groups were stimulated two weeks post boost with media alone, ID91 125 protein or each of 13 different 15mer peptide pools overlapping by 8mers of ID91 and evaluated 126 for proliferation and cytokine responses ( Figure 1D ). We observed that ID91+GLA-SE elicited 127

both CD4+ (Red) and CD8+ (Blue) T cell responses, albeit larger CD4+ TH1, while ID91-repRNA 128 + NLC largely drove CD8+ T cell proliferation and inflammatory cytokines ( Figure 1D ). While 129

there is some overlap in CD4+ and CD8+ responses driven by each immunization strategy, these 130 data demonstrate that RNA and protein differentially elicit CD4+ and CD8+ T cellular responses 131

to distinct antigen epitopes ( Figure 1D ) which may be beneficial for heterologous vaccine 132

approaches. This is congruent with clinical trials of ID93+GLA-SE where we have observed 133

protein-adjuvant vaccine-elicited immunogenicity to be dominated by CD4+ TH1 responses and 

We first evaluated ID91 repRNA and ID91-GLA-SE prophylactic immunizations in C57BL/6 mice 149

for immunogenicity as well as protection from infection six weeks after a single immunization as 150 a stringent criteria for advancing this platform. A single vaccination with ID91+GLA-SE induced 151

robust CD4+ CD44+ TH1 T cells expressing IFNγ, IL-2 and TNF (Figure 2A) , but negligible CD8+ 152 CD44+ cytokine producing T cells ( Figure 2B) . Conversely, ID91 repRNA + NLC trended towards 153

higher induction of IFNγ, IL-2 or TNF producing CD8+ CD44+ T cells ( Figure 2B ) as well as 154 moderate generation of TH1 CD4+ T cell responses (Figure 2A) . No significant IL17a or IL-21 155 expression was observed for any group (data not shown). Both vaccines induced a robust total 156

IgG humoral immune response to the ID91 fusion, significantly greater than the saline group but 157 not significantly different between the two platforms, with the bulk of this response being against 158

antigen Rv1886 ( Figure 2C) . Lastly, we observed that both ID91+GLA-SE and ID91 repRNA + 159 NLC significantly reduced lung bacterial burden, 0.55 and 0.43 log protection versus saline 160 respectively, three weeks post challenge with a low-dose aerosol (LDA 50-100 CFU) of Mtb 161

H37Rv ( Figure 2D) . These data demonstrate that the repRNA platform is immunogenic and 162 affords some prophylactic protection in a stringent preclinical mouse efficacy screening model of 163

TB. LDA challenge with Mtb H37Rv. n=7 per group. Asterisks represent a statistically significant 174 difference from saline using One-way ANOVA with Dunnett's multiple-comparison test. All data 175

are representative of two independent repeated experiments. * p < 0.05, ** p < 0.01, *** p < 0.001 176 and **** p < 0.0001. 177

Next, we evaluated the protein and RNA-based platforms for immunogenicity and protection 178

against an ultra-low dose (ULDA, 1-8 bacteria) of H37Rv challenge using heterologous, 179

homologous and combination prime-boost strategies. For combination strategies mice were given 180 both ID91+GLA-SE and ID91 repRNA + NLC i.m. in separate limbs at prime and boost time points 181

to avoid potential innate immune-mediated interference between the two modalities. We 182

hypothesized that driving CD4+ and CD8+ T cell responses may have an additive or synergistic 183 effect on immunogenicity and subsequent protection from the more physiologically relevant ULDA 184 challenge. We observed that two immunizations with ID91+GLA-SE enhanced protection in the 185 lung (0.743 log10) over a single dose (Table 1, Figure 3A ) which is in line with prior publications 186 from our group 55 . However, two immunizations with ID91 repRNA + NLC only afforded moderate 187 reduction of bacterial burden in the lung, 0.306 log10 (Table 1, Figure 3A ), which we believe may 188 be due to suboptimal timing between prime and boost vaccinations based on recent observations 189 outside the scope of this manuscript. Heterologous strategies also differed, with RNA-prime 190

protein-boost being the most efficacious regimen evaluated for reduction of lung bacterial load 191 (0.847 log10 reduction), followed closely by the combination regimen (0.809 log10 reduction) 192

(Table 1, Figure 3A ). While the combination regimen appears most protective from dissemination 193

to the spleen (1.419 log10 reduction from saline), this was not statistically significant due to a wide 194 standard error (Table 1, Figure 3B ). 195 regimens were low, and homologous ID93+GLA-SE was the only strategy to induce a statistically 201

significant response compared to saline ( Figure 3C) . We observed that combination and 202 homologous ID91+GLA-SE regimens induced the highest ID91-specific total IgG endpoint titers 203

in serum (EPT) post challenge, 7.45 log10 and 8.25 log10 respectively (Table 1, Figure 3D ). 204

They are followed by heterologous regimens, while the lowest total IgG induced was in the 205 homologous RNA cohort (Table 1, Figure 3D ). Similar trends were observed for ID91-specific 206

IgG1 ( Figure 3E ) and IgG2c ( Figure 3F) , with homologous protein and combination regimens 207 demonstrating the highest EPT and homologous RNA the lowest EPT. 208 Total IgG, E) IgG1 and F) IgG2c. CFU and EPT group means were compared to saline by ordinary 217

One-Way ANOVA and Dunnet's multiple comparisons test. Single cell suspensions isolated from 218 the lungs of animals 3 weeks post ULDA challenge were stimulated with ID91 protein (CD4+ T 219 cells) or ID91 peptide pool (CD8+ T cells) and evaluated for G) CD4+CD44+CD154+ and H) 220 CD8+CD44+ T cell expression of IFNγ, IL-2 and TNF by flow cytometry. n=4 per group. All data 221

are representative of two independent repeated experiments. Cytokine expression was compared 222 using a One-Way ANOVA and Dunnet's multiple comparisons test. * p < 0.05, ** p < 0.01, *** p < 223 0.001 and **** p < 0.0001. 224

Interestingly we did not observe significant differences in ID91-specific stimulation of individual 225

cytokines IL-2, GM-CSF or IL-17A from CD4+ nor CD8+ T cells between treatment groups. 226

However, CD4+ T cell TNF expression was statistically higher in heterologous RNA prime, protein 227

boost and combination regimens and CD8+ T cell TNF expression was significantly higher in the 228 combination regimen. Given the relative paucity of strong CD8+ epitopes in ID91 antigens, it was 229 not a surprise to observe expression of CD107a on CD8+CD44+ T cells post challenge to be 230 statistically similar between cohorts (data not shown). We also examined polyfunctional CD4+ 231

and CD8+ T cell responses by flow cytometry from each cohort after ex vivo stimulation of lung 232 cells and found only the combination regimen to induce significantly higher total magnitude of 233 responses for both CD4+ and CD8+ subsets (Figure 3G, 3H, Table 1 ). While not significant, there 234 is a trend for most robust polyfunctional CD4+ T cell responses in regimens that include at least 235 one arm including protein immunizations. We observed the composition of polyfunctional cells to 236 be relatively similar (Figure 3G, 3H (Figure 3G, 3H) . 240

These data provide the first report of a replicating RNA-based vaccine strategy being evaluated 242

in the Mtb mouse challenge model and showing efficacy in heterologous and combination 243 regimens. A key advantage of RNA platforms is their ability stimulate antigen-specific CD8+ T 244 cells and antibody responses which both aid in the control of intracellular infections. As a result, 245

heterologous and co-immunization strategies that combine protein and nucleic acid vaccines is a 246 promising approach to inducing protective immunity through CD4+ and CD8+ T cell-mediated 247 responses 56,57 . We observed that heterologous and combination regimens were moderately 248 additive in reducing pulmonary bacterial burden in this preclinical model. While no single 249

immunological endpoint (total IgG, IgG1, IgG2c, IgA EPT, TH1 CD4+ or CD8+ T cells) correlated 250 with protective efficacy, there are interesting trends that may be further explored and optimized. 251

Indeed, our data suggest that meeting thresholds for specific combinations of responses, versus 252 single endpoints, may better correlate with protective efficacy in this model. Additionally, future 253

interrogations should examine other immune correlates that are showing promise including IgM, 254

IgA as well as localization and kinetics of CD4+ and CD8+ T cell responses 43,58 . The mucosal or 255 aerosol delivery of repRNA in specialized delivery formulations may also help drive pulmonary-256 specific immunity against Mtb and these strategies are currently being evaluated. 257

The landscape of TB vaccines is ready for a dramatic surge forward. While ID91 served here as 258 a proof-of-concept antigen which afforded some protection from bacterial burden, epitope 259 mapping demonstrated that ID91 contains few dominant CD8+ T cell epitopes in the C57BL/6 260 mouse model. Future work that incorporates antigens containing high priority CD8+ T cell 261 epitopes 29,59,60 should be prioritized. The speed of RNA vaccine development and ability to rapidly 262 swap antigens lends itself well to the need of TB vaccines since global regions harbor different 263

predominant lineages 61 and tailoring vaccines to meet regional needs may further help improve 264 efficacy. Additionally, evaluating alternative repRNA expression strategies and alternative timing 265 between prime and boost immunizations could be explored to optimize B and T cell responses to 266 the delivered antigens. For example, here we evaluated a prime/boost spaced 3 weeks apart and 267

have more recently established that 4-8 weeks between prime and boost drives better immune 268 responses in regimens that include the repRNA platform (unpublished and 49 ). We believe that 269 the moderate additive effect seen here with heterologous and combination regimens could be 270

significantly improved with these strategies. Homologous or heterologous regimens were also leveraged using the doses and regimens 308 outlined above. Combination cohorts received ID91+GLA-SE in the right hind limb followed by 309 ID91 repRNA + NLC in the left hind limb at both prime and boost timepoints in the same doses 310 described above. 311

Epitope mapping: Two weeks post boost splenocytes were isolated from cohorts of 312 ID91+GLA-SE or ID91 repRNA + NLC immunized mice and stimulated with ID91 protein antigen 313 (10µg/mL), overlapping peptides (10µg/mL) or media alone for 60 hours at 37 °C and 5% CO2 314

with proliferation dye (Violet Proliferation Dye, BD Biosciences). Peptides were generated in 315

15mer format with 8 amino acid overlaps for the ID91 fusion antigen, for a total of 125 peptides 316 (BioSynthesis). These 125 peptides make up 13 different pools of 5-10 peptides each. Cells were 317 then restimulated for two hours, brefeldin A was added directly to the plate and cells were allowed 318

to incubate for a further 4 hours. Cells were then washed and ICS and flow cytometry analysis 319

were performed as described below. 320

Flow cytometry. Intracellular flow cytometry was performed on splenocytes post immunization 321 but pre-challenge and lung homogenates post infection. Samples were incubated, washed and 322 stimulated as previously described 68 . Cells were stimulated with media alone, 10 µg/mL of 323 recombinant ID91, or 1 µg/mL phorbol myristate acetate (PMA) (Calbiochem) + 1 µg/mL 324 ionomycin (Sigma-Aldrich). Some sample stimulations also contained fluorescently labeled anti-325 mouse CD107a (1D4B, BioLegend). After stimulation samples were stained for markers of 326

interest using fluorescent conjugated antibodies as previously described 68 . Notably, all sample 327 stains were used at 10 µL/mL concentration. Primary surface staining included: anti-mouse CD4 328

(clone RM4-5, BioLegend), CD8a (clone 53-6.7, BioLegend), CD44 (clone IM7 , eBiosciences), 329 CD154 (clone MR1, BioLegend) and 1 µg/mL of Fc receptor block anti-CD16/CD32 (clone 93, 330 eBioscience) in PBS with 1% bovine serum albumin (BSA). Cells were then washed and fixed 331

using BD Biosciences Fix/Perm reagent for 20 min at RT. Intracellular staining was carried out in 332

Perm/Wash (BD Biosciences) reagent with anti-mouse GMCSF (clone MP1-22E9, BioLegend), 333

IFN-γ (clone XMG1.2, Invitrogen), IL-2 (clone JES6-5H4, eBioscience), IL-17A (clone Tc11-334

1BH10.1, BioLegend), TNF-α (clone MP6-XT22, eBioscience), and IL-21 (mhalx21, 335 eBiosciences) for 10 min at RT. Samples were then incubated in 4% paraformaldehyde for 20 336 min to fix, decontaminate and remove from the containment facility before washing and 337 resuspension in PBS + 1% BSA. An LSRFortessa flow cytometer (BD Bioscience) was used for 338 sample acquisition, analysis was performed using FlowJo v10. 339 EPT ELISA. Serum was collected from terminal bleeds immediately after euthanasia, at post 340 boost or post infection timepoints. BALf was collected from post infection timepoints immediately 341 after euthanasia. Serum samples were diluted 1:100, and BALf samples were added directly 342

(neat) to plates coated with 2 µg/mL of ID91, Rv1886, Rv2389, Rv3478, or Rv3619. After an 343 overnight incubation, plates were exposed to HRP-conjugated IgA, Total IgG, IgG1, or IgG2c 344 (Southern Biotech). Plates were then developed with tetramethylbenzidine substrate and stopped 345 with 1 N H2SO4. Plates were read at 450nm with 570nm background subtraction. EPT were 346 calculated using regression analysis of sample dilution and O.D. on GraphPad Prism. 347

Bacterial burden/CFU. 24 hours to 3 weeks post infection with Mtb, 3-7 mice per group were 348 euthanized with CO2. Lung and spleen tissue from infected animals was isolated and homogenized in 5 mL of either RPMI + FBS (lung) or PBS + Tween-80 (Sigma-Aldrich, St. Louis, 350

Missouri, USA) CFU buffer (spleen) using an Omni tissue homogenizer (Omni International, 351

Kennesaw, GA, USA). Serial dilutions of homogenate were made in CFU buffer and aliquots were 352 plated on Middlebrook 7H11 agar plates and subsequently incubated at 37 °C and 5% CO2 for 2-353 3 weeks before colonies were counted. Bacterial burden, as CFU/mL, was calculated per organ 354

and is presented here as Log10 values. Reduction in the bacterial burden was calculated as the 355 difference in mean Log10 values between groups assessed. 356

Statistics. Bacterial burden, humoral and cellular immune responses were assessed using a 357

One-way ANOVA with Dunnets multiple comparison test between vaccinated groups and saline 358

control. Flow cytometry data was assessed using FlowJo v10 (BD) and SPICE (NIH) using the 359

Wilcoxon signed rank test as compared to untreated groups or One-way ANOVA with Dunnets 360 multiple comparison test. Statistical analyses were performed using GraphPad Prism 7 software. 361

Significant differences are labeled accordingly in the figures where * p < 0.05, ** p < 0.01, *** p < 362 0.001 and **** p < 0.0001, with methodology used previously by our group 68,70 . 363 364

World Health Organization

WHO Declares COVID-19 a Pandemic

World Health Organization Global TB Programme. Impact of the COVID-19 pandemic on TB 395 detection and mortality in 2020

Tuberculosis: a global health problem

How COVID vaccines shaped 2021 in eight powerful charts

Pretomanid: A novel therapeutic paradigm for treatment of drug resistant 401 tuberculosis

A novel ensemble based recommendation approach using network 403 based analysis for identification of effective drugs for Tuberculosis

An updated patent review on drugs for the treatment of 406 tuberculosis (2018-present)

Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline 409 against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis. Antimicrob Agents 410 Chemother 65

Systematic measurement of combination-drug landscapes to predict in vivo 412 treatment outcomes for tuberculosis

Feasibility of achieving the 2025 WHO global tuberculosis targets in South 415

combined analysis of 11 mathematical models

Cost-effectiveness and resource implications of aggressive action on 418 tuberculosis in China, India, and South Africa: a combined analysis of nine models

Data-driven model for the assessment of Mycobacterium tuberculosis 421 transmission in evolving demographic structures

Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: 424 systematic review and meta-analysis

Phase 2b Controlled Trial of M72/AS01(E) Vaccine to Prevent 426 Tuberculosis

Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis

Update on TB Vaccine Pipeline

Polyfunctional CD4(+) T Cells As Targets for 432 Tuberculosis Vaccination

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants 435 previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

IFN-γ-independent immune markers of Mycobacterium tuberculosis exposure

Functionally Overlapping Variants Control Tuberculosis Susceptibility in 440

Antigen-specific CD8(+) T cells and protective immunity to tuberculosis

Next generation: tuberculosis vaccines that elicit 444 protective CD8+ T cells

New TB vaccines: is there a requirement for CD8 T cells?

CD8+ T cells in tuberculosis

Comprehensive definition of human immunodominant CD8 antigens in 450 tuberculosis

CD8 T cells and Mycobacterium tuberculosis infection

Cytolytic CD8+ T cells recognizing CFP10 are recruited to the lung after 454 Mycobacterium tuberculosis infection

Murine airway luminal antituberculosis memory CD8 T cells by mucosal 457 immunization are maintained via antigen-driven in situ proliferation, independent of peripheral 458 T cell recruitment

Human CD8(+) T cells specific for Mycobacterium tuberculosis secreted 461 antigens in tuberculosis patients and healthy BCG-vaccinated controls in The Gambia

Protection against Mycobacterium 464 tuberculosis infection by CD8+ T cells requires the production of gamma interferon

Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+ and Lyt-2+ T 468 cells

Adoptive protection of the Mycobacterium tuberculosis-infected 470 lung. Dissociation between cells that passively transfer protective immunity and those that 471 transfer delayed-type hypersensitivity to tuberculin

Immunology of tuberculosis

Antimicrobial activity of MHC class I-restricted CD8+ T cells in human tuberculosis

CD8+ CTL from lungs of Mycobacterium 479 tuberculosis-infected mice express perforin in vivo and lyse infected macrophages

CD8(+) T cells participate in the memory immune response to 482

Mycobacterium tuberculosis

CD8+ T cell-mediated suppression of intracellular Mycobacterium 485 tuberculosis growth in activated human macrophages

Single mucosal, but not parenteral, immunization with recombinant adenoviral-488 based vaccine provides potent protection from pulmonary tuberculosis

Prevention of tuberculosis in macaques after intravenous BCG immunization. 491

The TB vaccine development pathway -An innovative approach to 493 accelerating global TB vaccine development

An Overview of the Development of New Vaccines 496 for Tuberculosis

The dawn of mRNA vaccines: The 498 COVID-19 case

RNA encoding the MPT83 antigen induces protective immune responses against 500

Mycobacterium tuberculosis infection

A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA 503 Provides Single, Low-Dose Protection against Zika

An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing 506 antibody and T cell responses in mice and nonhuman primates

Self-replicating alphavirus RNA vaccines

Alphavirus-based DNA vaccine breaks immunological tolerance by 511 activating innate antiviral pathways

Immune subdominant antigens as vaccine candidates against Mycobacterium 513 tuberculosis

Identification of human T cell antigens for the development of vaccines 516 against Mycobacterium tuberculosis

Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in 519 adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-520 controlled, phase 2a trial

Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine 522 against tuberculosis by lyophilization

Protection against tuberculosis with homologous or heterologous 525 protein/vector vaccine approaches is not dependent on CD8+ T cells

CD4 T cell help prevents CD8 T cell exhaustion and promotes control of 528 Mycobacterium tuberculosis infection

Robust IgM responses following intravenous vaccination with Bacille Calmette-531

Guérin associate with prevention of Mycobacterium tuberculosis infection in macaques

A Review on T Cell Epitopes Identified Using Prediction and Cell-Mediated Immune 534 Models for Mycobacterium tuberculosis and Bordetella pertussis

Antigens for CD4 and CD8 T 537 cells in tuberculosis. Cold Spring Harb Perspect Med 4, a018465

Global phylogeography of Mycobacterium tuberculosis and 540 implications for tuberculosis product development

From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the 543 frontiers of infectious diseases

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older 549 Adults

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

A defined tuberculosis vaccine candidate boosts BCG and protects against 553 multidrug-resistant Mycobacterium tuberculosis

Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with 556 Combined Drug and Immunotherapy Treatment. Vaccines (Basel)

Development and characterization of synthetic glucopyranosyl lipid adjuvant 559 system as a vaccine adjuvant

Subunit vaccine protects against a clinical isolate of Mycobacterium avium in 561 wild type and immunocompromised mouse models

The authors would like to express their gratitude to Seattle Children's Research Institute 366Leadership for their guidance, compassion, and mentorship.

The datasets generated and/or analyzed during the study presented here are available from the 368 corresponding authors on reasonable request.